姓 名:韩 亮
职称职务:特聘教授
联系邮箱:hanliang@suda.edu.cn
联系地址:云轩楼1325
个人简介:
一、学习工作经历
2021.10至今 我校,拉斯维加斯登录网站3133,特聘教授
2016.05-2021.09 我校,拉斯维加斯登录网站3133,副教授
2015.12-2016.04 哈尔滨工业大学,生命科学与技术学院,副教授
2012.09-2015.12 耶鲁大学,医学院,博士后
2007.09-2012.06 复旦大学,药剂学,理学博士
2003.09-2007.07 上海海洋大学,生物技术(海洋生物制药),理学学士
二、研究方向
1、脑靶向递药系统;
2、脑转移瘤靶向递药系统。
三、主要成绩及研究成果
聚焦于脑靶向递药开展研究工作,作为通讯/第一作者在Adv Mater、ACS Nano、Adv Funct Mater、Adv Sci、Small、Biomaterials、Acta Pharm Sin B、J Control Release等权威期刊发表论文20余篇(1区SCI论文16篇)。主持国家自然科学基金面上项目和青年科学基金项目、江苏省自然科学基金面上项目,参编外文专著1部。担任SCI期刊Chinese Chemical Letters、Asian J Pharm Sci青年编委。
(一) 科研项目
1、国家自然科学基金面上项目(32171381),2022.1-2025.12,主持;
2、国家自然科学基金面上项目(81973254),2020.1-2023.12,主持;
3、国家自然科学基金青年科学基金项目(81703428),2018.1-2020.12,主持;
4、江苏省自然科学基金面上项目(BK20191421),2019.7-2022.6,主持;
5、江苏省高等学校自然科学研究面上项目(17KJB350010),2017.9-2019.8,主持;
6、苏州市科技计划项目(SYS2019033),2019.7-2022.6,主持。
(二) 获奖荣誉
1、江苏省第六期“333高层次人才培养工程”第三层次培养对象;
2、2017年江苏省双创博士;
3、2021年度江苏省优秀专业学位硕士论文(缪彤彤);
4、2020年度江苏省优秀学术学位硕士论文(郭倩);
5、2018~2019年度苏州市自然科学优秀学术论文一等奖(缪彤彤);
6、2018~2019年度苏州市自然科学优秀学术论文三等奖(郭倩);
7、2014年上海市研究生优秀成果(学位论文)。
(三) 代表论文
1. Chen H, Zhou M, Zeng Y, Miao T, Luo H, Tong Y, Zhao M, Mu R, Gu J, Yang S, Han L*. Biomimetic Lipopolysaccharide-Free Bacterial Outer Membrane-Functionalized Nanoparticles for Brain-Targeted Drug Delivery. Adv Sci 2022, 2105854. DOI: 10.1002/advs.202105854. (一区,IF 16.806)
2. Han L*. Brain metastases: nanomedicine-boosted diagnosis and treatment. Medicine in Drug Discovery 2022, 13, 100111.
3. Han L*. Modulation of the Blood–Brain Barrier for Drug Delivery to Brain. Pharmaceutics 2021, 13(12), 2024. (二区,IF 6.321)
4. Han L*, Jiang C. Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies. Acta Pharm Sin B 2021, 11(8): 2306-2325. (一区,IF 11.413)
5. Ju X, Chen H, Miao T, Ni J, Han L*. Prodrug delivery using dual-targeting nanoparticles to treat breast cancer brain metastases. Mol Pharm 2021, 18(7): 2694-2702. (二区,IF 4.939)
6. Khan NU, Ni J, Ju X, Miao T, Chen H, Han L*. Escape from abluminal LRP1-mediated clearance for boosted nanoparticle brain delivery and brain metastasis treatment. Acta Pharm Sin B 2021, 11(5): 1341-1354. (一区,IF 11.413)
7. Ju X, Miao T, Chen H, Ni J, Han L*. Overcoming Mfsd2a-mediated low transcytosis to boost nanoparticle delivery to brain for chemotherapy of brain metastases. Adv Healthc Mater 2021, 10(9): 2001997. (一区,IF 9.933)
8. Ni J, Miao T, Su M, Khan NU, Ju X, Chen H, Liu F, Han L*. PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases. J Control Release 2021, 329: 934-947. (一区,IF 9.776)
9. Gao D, Zhu Q, Ruan J, Sun T*, Han L*. Polyplexes by polymerized dequalinium and bifunctional aptamer for mitochondrial targeting drug release to overcome drug resistance. ACS Appl Bio Mater 2020, 3(8): 5182-5192. (EI)
10. Miao T, Ju X, Zhu Q, Wang Y, Guo Q, Sun T, Lu C, Han L*. Nanoparticles surmounting blood-brain tumor barrier through both transcellular and paracellular pathways to target Brain Metastases. Adv Funct Mater 2019, 29(27): 1900259. (一区,IF 16.836)
11. Guo Q, Zhu Q, Miao T, Tao J, Ju X, Sun Z, Li H, Xu G, Chen H, Han L*. LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases. J Control Release 2019, 303: 117-129. (一区,IF 7.727)
12. Dong A#, Han L#, Shao Z, Fan P, Zhou X, Yuan H. Glaucoma drainage device coated with mitomycin C loaded opal shale microparticles to inhibit bleb fibrosis. ACS Appl Mater Interfaces 2019, 11(10): 10244-10253. (一区,IF 8.758)
13. Guo Q, Chang Z, Khan NU, Miao T, Ju X, Feng H, Zhang L, Sun Z, Li H, Han L*. Nanosizing noncrystalline and porous silica material naturally occurring opal shale for systemic tumor targeting drug delivery. ACS Appl Mater Interfaces 2018, 10(31): 25994-26004. (一区,IF 8.456)
14. Yu X#, Gou X#, Wu P#, Han L#, Tian D, Du F, Chen Z, Liu F, Deng G, Chen AT, Ma C, Liu J, Hashmi SM, Guo X, Wang X, Zhao H, Liu X, Zhu X, Sheth K, Chen Q, Fan L, Zhou J. Activatable protein nanoparticles for targeted delivery of therapeutic peptides. Adv Mater 2018, 30(7): 1705383. (一区,IF 25.809)
15. Han L, Cai Q, Tian D, Kong DK, Gou X, Chen Z, Strittmatter SM, Wang Z, Sheth KN, Zhou J. Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles. Nanomedicine 2016, 12(7): 1833-1842. (二区,IF 5.720)
16. Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J. Increased nanoparticle delivery to brain tumors by autocatalytic priming for improved treatment and imaging. ACS Nano 2016, 10(4): 4209-4218. (一区,IF 13.942)
17. Han L, Liu M, Ye D, Zhang N, Lim E, Lu J, Jiang C. Tumor cell membrane-targeting pH-dependent electron donor-acceptor fluorescence systems with low background signals. Biomaterials 2014, 35(9): 2952-2960. (一区,IF 8.557)
18. Han L, Guo Y, Ma H, He X, Kuang Y, Zhang N, Lim E, Zhou W, Jiang C. Acid active receptor-specific peptide ligand for in vivo tumor-targeted delivery. Small 2013, 9(21): 3647-3658. (一区,IF 7.514)
19. Han L, Ma H, Guo Y, Kuang Y, He X, Jiang C. pH-controlled delivery of nanoparticles into tumor cells. Adv Healthc Mater 2013, 2(11): 1435-1439. (一区,IF 4.880)
20. Han L, Li J, Huang S, Huang R, Liu S, Hu X, Yi P, Shan D, Wang X, Lei H, Jiang C. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials 2011, 32(11): 2989-2998. (一区,IF 7.404)
21. Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials 2011, 32(4): 1242-1252. (一区,IF 7.404)
22. Han L, Huang R, Liu S, Huang S, Jiang C. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm 2010, 7(6): 2156-2165. (二区,IF 5.400)
23. Huang R#, Han L#, Li J, Ren F, Ke W, Jiang C, Pei Y. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med 2009, 11(9): 754-763. (三区,IF 2.968)